Genetics-directed drug discovery for combating Mycobacterium tuberculosis infection

J Biomol Struct Dyn. 2017 Feb;35(3):616-621. doi: 10.1080/07391102.2016.1157037. Epub 2016 Jun 27.

Abstract

Mycobacterium tuberculosis (Mtb), the pathogen of tuberculosis (TB), is one of the most infectious bacteria in the world. The traditional strategy to combat TB involves targeting the pathogen directly; however, the rapid evolution of drug resistance lessens the efficiency of this anti-TB method. Therefore, in recent years, some researchers have turned to an alternative anti-TB strategy, which hinders Mtb infection through targeting host genes. In this work, using a theoretical genetic analysis, we identified 170 Mtb infection-associated genes from human genetic variations related to Mtb infection. Then, the agents targeting these genes were identified to have high potential as anti-TB drugs. In particular, the agents that can target multiple Mtb infection-associated genes are more druggable than the single-target counterparts. These potential anti-TB agents were further screened by gene expression data derived from connectivity map. As a result, some agents were revealed to have high interest for experimental evaluation. This study not only has important implications for anti-TB drug discovery, but also provides inspirations for streamlining the pipeline of modern drug discovery.

Keywords: connectivity map; drug discovery; medical genetics; target; tuberculosis.

MeSH terms

  • Antitubercular Agents / pharmacology*
  • Bacterial Proteins / genetics
  • Drug Discovery
  • Drug Resistance, Bacterial*
  • Gene Expression Profiling
  • Gene Expression Regulation, Bacterial / drug effects
  • Genetic Predisposition to Disease
  • Humans
  • Mycobacterium tuberculosis / drug effects*
  • Pharmacogenomic Variants*
  • Tuberculosis / drug therapy
  • Tuberculosis / genetics*
  • Tuberculosis / microbiology

Substances

  • Antitubercular Agents
  • Bacterial Proteins